Business Wire

Lilium Otsuka: Lilium® α-200, a Continuous Urine Volume Sensor, Will Be Launched in Japan

Del

Lilium Otsuka Co., Ltd., a subsidiary of Otsuka Holdings Co., Ltd. will begin selling the Lilium® α-200, a continuous, non-invasive bladder urine volume sensor, on November 2, 2015.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20151002005301/en/

Lilium alpha-200 is an innovative, hand-held urine volume sensor which measures not only bladder uri ...

Lilium alpha-200 is an innovative, hand-held urine volume sensor which measures not only bladder urine residual but also provides alerts on appropriate timing for clean-intermittent catheterization through continuous urine volume measurement. (Photo: Business Wire)

This product makes it possible to continuously monitor urination schedules in patients who have lost the urge to urinate. It is anticipated that this will alleviate the need for daily, lifestyle-restricting indwelling bladder (“Foley”) catheters and the anxiety of incontinence.

Problems with urination independence and control are known to determine the ability of patients to return home from the hospital, and impose a heavy burden on nursing and caregiving services. Lilium α-200 is expected to greatly contribute to the improvement of patient quality of life, and to reduce labor and improve the efficacy of those engaged in nursing and caregiving. Further, Lilium Otsuka expects to make a significant contribution to holistic treatments which impact the dignity of patients.

“For patients with loss of urge or urinary difficulty, the beauty of this product lies in its ability to accurately monitor the size of the bladder (a measure of volume of urine retained in the bladder) and the ability to schedule bathroom trips or self-catheterization.” said Dr. Osamu Yokoyama M.D., Ph.D., president of the Japanese Continence Society and professor on the Faculty of Medical Sciences, the University of Fukui, “As the Japanese Continence Society initiates a certified physician system next year to begin training doctors who can professionally manage continence care, this device is thought to provide a good method to support discharge of patients to their homes.”

About Lilium Otsuka

Lilium Otsuka is a subsidiary company of Otsuka Holdings Co., Ltd. (TOKYO:4578) established in Kanagawa, Japan. It is dedicated to standardizing the practice of measuring urinary volume as a “fifth vital sign” through developing innovative bladder health products.

About Lilium ® α-200

Lilium® α-200 is an innovative, hand-held urine volume sensor which works with two AA batteries. The device measures not only bladder urine residual but also provides alerts on appropriate timing for clean-intermittent catheterization through continuous urine volume measurement.

Contact information

Keiko Yoshimura
Lilium Otsuka Co., Ltd.
+81-42-704-3822
lilium_info@otsuka.jp
Website link: http://lilium200.jp/index-en.html

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

More than 70 Companies to Showcase Top Tech at CES Unveiled Paris20.10.2017 15:08Pressemelding

The Consumer Technology Association (CTA) today announced that more than 70 exhibitors will showcase their latest innovations at the now sold-out fifth annual CES Unveiled Paris The event will focus on the Internet of Things (IoT), connectivity and smart cities, and draw more than 600 attendees. CES Unveiled Paris will run from 2-7:30 PM on Tuesday, October 24, 2017 at the Palais Brongniart. Regional technology companies, top-tier media outlets, buyers and key industry influencers will come together at CES Unveiled Paris to get a direct look at the latest industry developments. The day kicks off with a CES news conference and CTA market trends presentation. Conference programming is followed by a tabletop exhibition & networking reception. Curated exhibitors will be there to showcase top tech from robotics and audio to smart home and augmented and virtual reality. Notable

Westinghouse Receives Regulatory Approval for Analysis Methodologies20.10.2017 12:15Pressemelding

Westinghouse Electric Company today announced that it has received approval from the U.S. Nuclear Regulatory Commission (NRC) for two new important analysis methodologies that will be used to upgrade Westinghouse- and Combustion Engineering-based nuclear steam supply system (NSSS) safety analyses. The approvals granted are for the new FULL SPECTRUMTM Loss of Coolant Accident (FSLOCATM) methodology and the Performance Analysis and Design Model software code update, PAD5. FSLOCA is capable of improved modeling of the transient response in a pressurized water reactor to the full spectrum of LOCA break sizes that could occur, and PAD5 is the next generation of the Westinghouse fuel rod design performance code. “These codes were developed to work in concert with each other to maximize analytical margin for nuclear utilities,” said Michele DeWitt, senior vice preside

Gilead Announces Multiple Scientific Presentations Demonstrating High Cure Rates in Difficult-to-Cure HCV Patients and Improved Long-Term Bone and Renal Safety of Vemlidy® in HBV Patients Switched from Viread®20.10.2017 12:03Pressemelding

Gilead Sciences, Inc. (NASDAQ: GILD) today announced results from Phase 2 and Phase 3 studies of its approved medicines for chronic hepatitis C virus (HCV) and hepatitis B virus (HBV) infection, adding to the body of evidence supporting Gilead’s viral hepatitis therapies in diverse patient populations. These and other data from more than 25 abstracts will be presented this week at The Liver Meeting® 2017, which begins today in Washington, D.C. Positive results from studies of Harvoni® (ledipasvir 90mg/sofosbuvir 400mg) in HCV-infected patients with severe renal impairment, Epclusa® (sofosbuvir 400mg/velpatasvir 100mg) in HCV-infected liver transplant recipients and Vosevi® (sofosbuvir 400mg/velpatasvir 100mg/voxilaprevir 100mg) in NS5A-inhibitor experienced HCV-infected patients will be presented during poster sessions on October 21 and October 22. In addition, updated results f

SP3H Announces That It Has Obtained a €1.2 Million European Union Grant for Its Intelligent and Clean Vehicle (VIP) Project20.10.2017 10:47Pressemelding

SP3H is proud to announce joining the very select circle of the 10 French winners of the H2020 SME Instrument Phase 2 program since 2014. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171020005325/en/ Last summer VIP received the very prestigious SME instrument phase 2 H2020 label in the "transport & smart cities mobility" category. With an overall budget of € 1.7 million, VIP is subsidized by the European Union at a rate of 70% or €1.2 million. The framework contract was officially signed early October. VIP is the pre-industrialization program for Fuelbox sensors, the world's first miniaturized scanner capable of analyzing the quality of fuels on board vehicles. The heart of the program remains closely linked to the reduction of CO2 and pollutant emissions from vehicle

Kennedy Wilson and Kennedy Wilson Europe Real Estate Plc Complete Merger, Creating $8 Billion Global Real Estate Company20.10.2017 10:00Pressemelding

Global real estate investment company Kennedy-Wilson Holdings, Inc. (NYSE:KW) (“KW”) today announced the completion of its merger with Kennedy Wilson Europe Real Estate Plc (LSE:KWE) (“KWE”). The transaction creates a leading global real estate investment and asset management platform with an $8 billion enterprise value. “This transformative combination with KWE represents an exciting new chapter for our company,” said William J. McMorrow, Chairman and CEO of KW. “We are moving towards a simplified corporate structure that provides more recurring income from stable property cash flows and greater upside potential from value-enhancing initiatives worldwide. We are well positioned for future growth and to continue our track record of generating attractive risk-adjusted returns on our invested capital.” “We are thrilled to combine the financial strength of KW and KWE to continu

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom